AVL-292 is primarily used in biochemical and pharmaceutical research as a potent and selective inhibitor of Bruton's tyrosine kinase (BTK). This inhibition plays a critical role in modulating B-cell receptor signaling, making AVL-292 a valuable tool in the study of B-cell malignancies and autoimmune diseases. It is utilized in preclinical studies to evaluate the therapeutic potential of BTK blockade in conditions such as chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma, and rheumatoid arthritis. Due to its high selectivity and irreversible binding mechanism, AVL-292 enables sustained suppression of BTK activity, allowing researchers to investigate downstream signaling effects and optimize dosing regimens in experimental models. Its application is mainly confined to laboratory research and drug development rather than clinical use.